Trial Profile

Phase 2 Trial of NanoPac Focal Therapy for Prostate Cancer in Subjects Undergoing Radical Prostatectomy

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 08 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions
Sponsors Nanology

Most Recent Events

06 Jun 2023 Results of 7 studies (NCT00666991, NCT03636256, NCT03077659, NCT04221828, NCT03029585, NCT03077685, NCT04314895) assessing safety findings in subjects co-administered LSAM-PTX or LSAM-DTX and common SOC therapies for treatment of carcinomas, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
25 May 2021 Status changed from recruiting to discontinued due to lack of enrollment.
04 Nov 2020 According to a NanOlogy media release, first patient has been enrolled in this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com